Literature DB >> 19167761

HLA-B27 polymorphism at position 116 critically influences the association with TAP/tapasin, intracellular trafficking and conformational homodimers formation.

M A Blanco-Gelaz1, B Suárez-Alvarez, R Díaz-Peña, C López-Larrea.   

Abstract

HLA-B27 confers susceptibility to ankylosing spondylitis but AS disease mechanisms remain unknown. We determined here the effect of polymorphism and tapasin dependence on the expression, intracellular maturation and homodimer formation among HLA-B27 subtypes. We found that B*2709 with a histidine at position 116 was strongly associated with the transporter associated with antigen processing complex, correlated with lower, non-conformational expression on the cell surface, delayed maturation rate and minimal conformational and non-conformational homodimer formation. In contrast, B*2705 showed a low dependence for transporter associated with antigen processing, faster intracellular maturation and increased levels of homodimeric forms. The absence of tapasin significantly influenced the rate of intracellular maturation of B*2709, showing faster transport out of the endoplasmic reticulum, but similar to that of B*2705. All B27 subtypes examined were unable to express conformational homodimeric forms in the absence of tapasin. This study suggests that HLA-B27 polymorphism drives the tapasin dependency, rates of intracellular maturation and expressions of homodimers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19167761     DOI: 10.1016/j.molimm.2008.11.023

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  8 in total

1.  Residue 81 confers a restricted C-terminal peptide binding motif in HLA-B*44:09.

Authors:  Trevor Huyton; Heike Schumacher; Rainer Blasczyk; Christina Bade-Doeding
Journal:  Immunogenetics       Date:  2012-06-16       Impact factor: 2.846

2.  Mutational analysis reveals a complex interplay of peptide binding and multiple biological features of HLA-B27.

Authors:  Begoña Galocha; José A López de Castro
Journal:  J Biol Chem       Date:  2010-10-02       Impact factor: 5.157

Review 3.  The interplay between HLA-B27 and ERAP1/ERAP2 aminopeptidases: from anti-viral protection to spondyloarthritis.

Authors:  C Vitulano; V Tedeschi; F Paladini; R Sorrentino; M T Fiorillo
Journal:  Clin Exp Immunol       Date:  2017-08-30       Impact factor: 4.330

4.  Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis.

Authors:  Paul Bowness; Anna Ridley; Jacqueline Shaw; Antoni T Chan; Isabel Wong-Baeza; Myles Fleming; Fraser Cummings; Andrew McMichael; Simon Kollnberger
Journal:  J Immunol       Date:  2011-01-19       Impact factor: 5.422

5.  Pathogenicity of Misfolded and Dimeric HLA-B27 Molecules.

Authors:  Antony N Antoniou; Izabela Lenart; David B Guiliano
Journal:  Int J Rheumatol       Date:  2011-03-30

6.  The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09.

Authors:  Alberto Cauli; Jacqueline Shaw; Joanna Giles; Hiroko Hatano; Oliwia Rysnik; Sravan Payeli; Kirsty McHugh; Grazia Dessole; Giovanni Porru; Elisabetta Desogus; Sarah Fiedler; Soraya Hölper; Amanda Carette; Miguel Angel Blanco-Gelaz; Alessandra Vacca; Matteo Piga; Valentina Ibba; Pietro Garau; Giorgio La Nasa; Carlos López-Larrea; Alessandro Mathieu; Christoph Renner; Paul Bowness; Simon Kollnberger
Journal:  Rheumatology (Oxford)       Date:  2013-06-26       Impact factor: 7.580

7.  Selector function of MHC I molecules is determined by protein plasticity.

Authors:  Alistair Bailey; Neil Dalchau; Rachel Carter; Stephen Emmott; Andrew Phillips; Jörn M Werner; Tim Elliott
Journal:  Sci Rep       Date:  2015-10-20       Impact factor: 4.379

Review 8.  Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation.

Authors:  Marek Wieczorek; Esam T Abualrous; Jana Sticht; Miguel Álvaro-Benito; Sebastian Stolzenberg; Frank Noé; Christian Freund
Journal:  Front Immunol       Date:  2017-03-17       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.